SNCA and Parkinson disease: Ambroxol, an anti-mucosal drug, augmented glucocerebrosidase (GBA) activity, decreased α-synuclein, and phosphorylated α-synuclein concentrations in PD mouse models [110] and in PD patients (+/−mutant GBA) [111].